WASHINGTON, Oct 23, 2021 (BSS/XINHUA) - Pfizer and its partner BioNTech 
said their COVID-19 vaccine is safe and 90.7 percent effective against 
symptomatic COVID-19 in children ages 5 to 11.

  The companies revealed the data in a document posted Friday ahead of a 
meeting of advisers to the U.S. Food and Drug Administration (FDA) scheduled 
for next Tuesday.

  Pfizer and BioNTech are applying FDA emergency use authorization (EUA) of a 
two-dose regimen of their 10-microgram dose for children ages 5 to 11. The 
two doses would be administered three weeks apart.

  The data show that the two-dose primary series of the vaccine given to 
children from 5 to less than 12 years of age confers a high degree of 
protective efficacy against COVID-19 during a period when the Delta variant 
of concern predominates in the United States.

  The FDA's Vaccines and Related Biological Products Advisory Committee is 
scheduled to meet on Oct. 26 to discuss whether to authorize the vaccine for 
children ages 5 to 11.

  If authorized, it would be the first COVID-19 vaccine for younger children.

  The Pfizer-BioNTech vaccine is currently fully approved for people ages 16 
and older, and has an EUA for children ages 12 to 15.